About
Reformulations of established drugs
Areas of Focus
Categories
Small Molecule PharmaceuticalDrug Delivery & FormulationMiddle East
Team (11)
Clinical Trials (14)
View allTotal Trials
14
As Lead Sponsor
14
As Collaborator
0
Total Enrollment
837
By Phase
PHASE3: 3PHASE2: 3PHASE1: 6PHASE1/PHASE2: 2
By Status
COMPLETED: 10ACTIVE_NOT_RECRUITING: 2WITHDRAWN: 2
Clinical Trials Pipeline14 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT04006210Lead Sponsor
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
PHASE3Active, not recruiting
381 participants
Started: Sep 30, 2019 · Completed: Feb 28, 2027
NCT03462043Lead Sponsor
A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension
PHASE3Withdrawn
Started: Apr 10, 2018 · Completed: Dec 30, 2018
NCT02782481Lead Sponsor
A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations
PHASE3Withdrawn
Started: Aug 31, 2016 · Completed: Oct 15, 2018
NCT02726386Lead Sponsor
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
PHASE2Active, not recruiting
214 participants
Started: May 4, 2016 · Completed: Feb 28, 2027
NCT02577523Lead Sponsor
A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease
PHASE2Completed
38 participants
Started: Dec 29, 2015 · Completed: Jan 31, 2017
Locations (1)
Headquarters
Rehovot, Israel
Map
Loading map...